Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation

Highlights • EGFR-TKI treatment for NSCLC with EGFR mutation shows high response rate and long PFS. • But several cases showed poor response. • In NEJ002 study, 8.2% cases were showed no response to the gefitinib treatment. • Heavy smoking and the L858R mutation may be related to poor response....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-05, Vol.88 (2), p.181-186
Hauptverfasser:	Fukuhara, Tatsuro, Maemondo, Makoto, Inoue, Akira, Kobayashi, Kunihiko, Sugawara, Shunichi, Oizumi, Satoshi, Isobe, Hiroshi, Gemma, Akihiko, Harada, Masao, Yoshizawa, Hirohisa, Kinoshita, Ichiro, Fujita, Yuka, Saijo, Yasuo, Hagiwara, Koichi, Morita, Satoshi, Nukiwa, Toshihiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carboplatin–paclitaxel Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Clinical Trials, Phase III as Topic Disease-Free Survival EGFR Exons - drug effects Exons - genetics Female Gefitinib Hematology, Oncology and Palliative Medicine Humans L858R mutation Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Middle Aged Mutation - drug effects Mutation - genetics NEJ002 Paclitaxel - administration & dosage Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Retrospective Studies Sequence Deletion - drug effects Sequence Deletion - genetics Smoking Smoking - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • EGFR-TKI treatment for NSCLC with EGFR mutation shows high response rate and long PFS. • But several cases showed poor response. • In NEJ002 study, 8.2% cases were showed no response to the gefitinib treatment. • Heavy smoking and the L858R mutation may be related to poor response.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2015.02.004